123 related articles for article (PubMed ID: 19624692)
1. Differential outcomes in 3 types of acute antibody-mediated rejection.
Rafiq MA; de Boccardo G; Schröppel B; Bromberg JS; Sehgal V; Dinavahi R; Murphy B; Akalin E
Clin Transplant; 2009; 23(6):951-7. PubMed ID: 19624692
[TBL] [Abstract][Full Text] [Related]
2. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development.
Rebellato LM; Ozawa M; Verbanac KM; Catrou P; Haisch CE; Terasaki PI
Clin Transpl; 2006; ():241-53. PubMed ID: 18365382
[TBL] [Abstract][Full Text] [Related]
3. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts.
Lachmann N; Terasaki PI; Budde K; Liefeldt L; Kahl A; Reinke P; Pratschke J; Rudolph B; Schmidt D; Salama A; Schönemann C
Transplantation; 2009 May; 87(10):1505-13. PubMed ID: 19461487
[TBL] [Abstract][Full Text] [Related]
4. De novo donor specific antibodies and patient outcomes in renal transplantation.
DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA
Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts.
Cooper JE; Gralla J; Chan L; Wiseman AC
Clin Transpl; 2011; ():359-64. PubMed ID: 22755431
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
[TBL] [Abstract][Full Text] [Related]
7. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
Lee PC; Ozawa M
Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
[TBL] [Abstract][Full Text] [Related]
8. Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification.
Gibney EM; Cagle LR; Freed B; Warnell SE; Chan L; Wiseman AC
Nephrol Dial Transplant; 2006 Sep; 21(9):2625-9. PubMed ID: 16644776
[TBL] [Abstract][Full Text] [Related]
9. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
Hardinger KL; Murillo D
Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
[TBL] [Abstract][Full Text] [Related]
10. Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC.
Pavlakis M
Clin Transpl; 2009; ():343-5. PubMed ID: 20524296
[TBL] [Abstract][Full Text] [Related]
11. Detailed examination of HLA antibody development on renal allograft failure and function.
Zhu L; Lee PC; Everly MJ; Terasaki PI
Clin Transpl; 2008; ():171-87. PubMed ID: 19711514
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads.
Amico P; Hönger G; Mayr M; Steiger J; Hopfer H; Schaub S
Transplantation; 2009 Jun; 87(11):1681-8. PubMed ID: 19502960
[TBL] [Abstract][Full Text] [Related]
13. Blood group Lewis alloantibodies cause antibody-mediated rejection in renal transplant recipients.
Boratyńska M; Banasik M; Hałoń A; Patrzałek D; Klinger M
Transplant Proc; 2007 Nov; 39(9):2711-4. PubMed ID: 18021965
[TBL] [Abstract][Full Text] [Related]
14. Intact HLA not beta2m-free heavy chain-specific HLA class I antibodies are predictive of graft failure.
Cai J; Terasaki PI; Anderson N; Lachmann N; Schönemann C
Transplantation; 2009 Jul; 88(2):226-30. PubMed ID: 19623018
[TBL] [Abstract][Full Text] [Related]
15. Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation.
Li X; Ishida H; Yamaguchi Y; Tanabe K
Transpl Int; 2008 Dec; 21(12):1145-52. PubMed ID: 18803618
[TBL] [Abstract][Full Text] [Related]
16. Donor-directed HLA antibodies before and after transplantectomy detected by the luminex single antigen assay.
Billen EV; Christiaans MH; Lee J; van den Berg-Loonen EM
Transplantation; 2009 Feb; 87(4):563-9. PubMed ID: 19307795
[TBL] [Abstract][Full Text] [Related]
17. Desensitization protocols and their outcome.
Marfo K; Lu A; Ling M; Akalin E
Clin J Am Soc Nephrol; 2011 Apr; 6(4):922-36. PubMed ID: 21441131
[TBL] [Abstract][Full Text] [Related]
18. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant.
Kaczmarek I; Deutsch MA; Kauke T; Beiras-Fernandez A; Schmoeckel M; Vicol C; Sodian R; Reichart B; Spannagl M; Ueberfuhr P
Exp Clin Transplant; 2008 Sep; 6(3):229-35. PubMed ID: 18954302
[TBL] [Abstract][Full Text] [Related]
19. Blood levels of donor-specific human leukocyte antigen antibodies after renal transplantation: resolution of rejection in the presence of circulating donor-specific antibody.
Higgins R; Hathaway M; Lowe D; Lam F; Kashi H; Tan LC; Imray C; Fletcher S; Zehnder D; Chen K; Krishnan N; Hamer R; Briggs D
Transplantation; 2007 Oct; 84(7):876-84. PubMed ID: 17984841
[TBL] [Abstract][Full Text] [Related]
20. Time of occurrence of kidney acute antibody-mediated allograft rejection/acute cellular rejection and cell senescence: implications for function outcome.
Arvizu-Hernández M; Morales-Buenrostro LE; Vilatoba-Chapa M; Mancilla-Urrea E; Uribe-Uribe N; Avila-Casado MC; de Leo C; Arvizu A; Gonzalez JL; Torres J; Gabilondo B; Correa-Rotter R; Alberú J
Transplant Proc; 2010 Sep; 42(7):2486-92. PubMed ID: 20832529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
